T he term angina pectoris, proposed >2 centuries ago, is commonly considered to be synonymous with obstructive atherosclerotic epicardial coronary artery disease (CAD). The frequently reported association among angina pectoris (central chest pain), myocardial ischemia, and coronary atherosclerosis has reinforced the concept that anginal pain and myocardial ischemia are almost exclusively caused by obstructive CAD. 1 Diagnostic and therapeutic strategies for angina pectoris in its 2 main forms of presentation, namely, chronic stable angina and acute coronary syndrome (ACS), have been and continue to be based on the obstructive CAD paradigm. Current recommendations in international angina management guidelines are informed by the notion that coronary atheromatous plaques are the main cause for myocardial ischemia. [2] [3] [4] Nonetheless, the latest European Society of Cardiology guidelines 4 acknowledge the pathogenic role of coronary artery spasm and coronary microvascular dysfunction (CMD) in myocardial ischemia, and the "2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guidelines for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease" 2 mention that microvascular disease, with vascular reactivity related to abnormalities in microvascular and endothelial function, contributes to ischemia to a greater extent in women than in men.
Although strategies based on the classical pathophysiological concepts are useful for the management of a substantial proportion of patients with chronic stable angina and the majority of patients with ACS, the paradigm that obstructive CAD is synonymous with myocardial ischemia needs to be revised because it is not universally applicable to individuals presenting with chronic stable angina 5 or to a proportion of patients with ACS. 6 Indeed, functional mechanisms have been documented that can cause myocardial ischemia in the absence of obstructive CAD. Epicardial coronary artery spasm, as initially proposed by Prinzmetal et al 7 and further documented and characterized by Maseri et al, 8 are striking examples. Evidence gathered over the past 30 years has made it clear that functional and structural mechanisms affecting prearterioles, arterioles, and capillaries represent yet another major cause for myocardial ischemia (Figure 1 ) in the absence of obstructive CAD [9] [10] [11] [12] [13] and can also trigger ischemia in patients with CAD. 14 The initial descriptions of angina developing in the absence of CAD gave rise to the rather ill-defined concepts of chest pain with normal coronary arteries or cardiac syndrome X. [15] [16] [17] The term microvascular angina (MVA) was originally proposed by Cannon and Epstein 16 in 1988 to describe patients with normal coronary arteriograms and evidence of myocardial ischemia caused by a disorder of the coronary microvasculature. The term MVA has gained acceptance over other denominations to define patients with angina despite nonobstructive CAD or with completely normal coronary angiograms. It could be argued, however, as it will be elaborated throughout -this article, that the term MVA should be applicable to all forms of angina/ischemia triggered by CMD despite the absence or presence of CAD, rather than restricting the term to conditions characterized by myocardial ischemia in the absence of obstructive CAD.
Progress in the understanding of MVA was slow because studies were usually underpowered, used either restrictive inclusion criteria, or included rather heterogeneous groups of patients. Moreover, tools for the assessment of the microcirculation were not available until recently in clinical practice. Probably as a result of these factors, chest pain with normal coronary arteries was considered to be an infrequent condition, often noncardiac in origin, and with a benign prognosis. 17 Studies in the past decade, however, have shown that angina in the absence of obstructive CAD is more common than initially thought, 5, 18 and CMD is also associated with myocardial ischemia and adverse clinical outcomes. [19] [20] [21] As proposed by Camici and Crea, 22 CMD can be the underlying pathogenic mechanism in a large proportion of angina cases with and without CAD (Table 1) . CMD may result from functional or structural abnormalities occurring at the site of the coronary microcirculation, and the relative roles these mechanisms play may vary across different clinical settings and also among patients. The present article discusses the fundamental role of CMD in the pathogenesis of ischemic heart disease, the clinical characteristics of patients presenting with microvascular angina, and possible diagnostic and therapeutic strategies. We also discuss how CMD can lead to chronic stable or acute forms of myocardial ischemia 6, [23] [24] [25] [26] and impair clinical outcomes.
MYOCARDIAL ISCHEMIA: PATHOPHYSIOLOGY: THE ROLE OF CMD Anatomy and Physiological Responses of the Coronary Circulation
The myocardium is an aerobic tissue that requires continuous perfusion with oxygenated blood to generate the energy necessary for its contraction. Under baseline conditions, oxygen extraction from the arterial blood is close to 60% to 70%, and therefore a rise in myocardial oxygen demand can only be met by an appropriate increase in coronary blood flow (CBF). Under physiological circumstances, the coronary circulation provides an adequate match between myocardial oxygen demand and supply. The coronary arterial system comprises 3 compartments, each with a different function, whose anatomic borders cannot be clearly delineated in vivo (Figure 2 ). The proximal compartment is represented by the epicardial arteries, which have a capacitance function and offer little resistance to CBF. These vessels range from 5.0 to 0.5 mm in diameter and run on the surface of the heart before branching off into the myocardium and giving rise to intramural vessels. Epicardial coronary arteries have a thick wall with 3 well-demarcated layers or tunicae: (1) the adventitia, which harbors the vasa vasorum and nerves; (2) the media, with a circular array of vascular smooth muscle (that modulates vessel diameter changes); and (3) the intima, on which sits the vascular endothelium. The more distal intramyocardial branches have thinner walls and do not possess vasa vasorum. During systole, the epicardial arteries accumulate elastic energy as they increase their blood content up to ≈25%. At the onset of diastole, this elastic energy is converted into kinetic energy that contributes to the prompt reopening of the intramyocardial vessels after having been compressed during systole. This mechanism is of particular relevance considering that 90% of CBF takes place in diastole. 27 The intermediate compartment is represented by the prearteriolar vessels, with diameters ranging from ≈500 to 100 μm and characterized by a measurable pressure drop along their length. Their specific function is to maintain pressure at the origin of downstream arterioles within a narrow range when changes in coronary perfusion pressure or flow take place. The more proximal vessels (500 to 150 μm in diameter) are more responsive to changes in flow, whereas the more distal vessels (150 to 100 μm) are more sensitive to changes in pressure. 28 Functionally, their vasomotor actions are not under the direct control of diffusible myocardial metabolites.
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The distal compartment is represented by the arterioles, which have diameters <100 μm and are characterized by a considerable drop in pressure along their path. Arterioles are the site where metabolic Figure 1 . The role of coronary microvascular dysfunction in the pathogenesis of ischemic heart disease. Ischemic heart disease can result from several mechanisms, including atheromatous plaques occluding the epicardial coronary arteries, coronary artery spasm, and coronary microvascular dysfunction (CMD). Similar to obstructive epicardial disease, CMD can lead to myocardial ischemia by impairing the ability of the coronary circulation to increase coronary blood flow in response to an increased myocardial oxygen demand. CMD can result from an abnormal vasodilatory ability of the microvasculature, compressive external forces affecting the intramural microvessels, or microvascular spasm. CMD is typically the cause of myocardial ischemia in individuals with angina despite completely normal coronary arteriograms (primary microvascular angina), but it can also trigger myocardial ischemia in several other clinical conditions, including patients with cardiomyopathies and those with obstructive coronary artery disease. VSMC indicates vascular smooth muscle cell.
regulation of CBF takes place because their tone is influenced by substances produced by the surrounding cardiac myocytes. 29, 30 Prearterioles, arterioles, and capillaries constitute the coronary microcirculation. Under resting conditions, the tone of the coronary microvasculature is high, but rapid changes in arteriolar diameter can take place to allow the coronary circulation to promptly increase CBF in response to increased myocardial oxygen demand (ie, functional hyperemia). This initial arteriolar response, driven by the strict cross-talk that exists between these vessels and the contracting cardiomyocytes, represents the basis for metabolic vasodilatation. 31 Such a drop in arteriolar resistance, to increase CBF, subsequently drives a number of vascular adaptations that involve all upstream coronary vessels. Capillaries and venules are also an important component of the coronary microcirculation, and both structural and functional abnormalities at this level (ie, capillary rarefaction or microembolization) can contribute to the development of myocardial ischemia. An in-depth discussion of these mechanisms is beyond the scope of this article. Interested readers are referred to recently published review articles.
28,32

The Different Causes of Transient Myocardial Ischemia
Myocardial ischemia invariably results from an imbalance between myocardial metabolic demand and CBF. Inadequate blood supply can be caused by anatomic or functional abnormalities in all and each of the compartments of the coronary circulation. In addition, extravascular factors, such as decreased diastolic time and elevated extravascular pressure affecting the coronary microcirculation, can also contribute to the development of myocardial ischemia (Figures 1 and 2 ).
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Ischemia Caused by Abnormalities in the Epicardial Circulation
Obstructive CAD Atheromatous plaques can reduce the lumen of the vessel and lead to a progressive reduction of coronary flow reserve (CFR) and impaired myocardial perfusion. This mechanism can lead to typical exercise-or emotional stress-induced ischemic symptoms and signs, including silent ischemia. 34 Coronary artery spasm 7, 8 can cause myocardial ischemia as a result of a primary reduction of CBF. Characteristically, patients with coronary artery spasm present with angina at rest associated with transient ST segment elevation or depression, which responds rapidly to the administration of nitrates. 35 Spasm may occur at the site of an atheromatous plaque or in angiographically normal vessels. 35 Intracoronary ergonovine or acetylcholine (ACh), used for diagnosis, can provoke coronary spasm and reproduce the symptoms and ECG changes that occur spontaneously in patients with vasospastic angina.
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Ischemia Caused by CMD
CMD can lead to myocardial ischemia by (1) impairing the ability of the coronary microcirculation to increase CBF in response to an increased myocardial oxygen demand, an effect that is equivalent to that exerted by flow-limiting epicardial coronary artery stenoses; or (2) resulting in coronary microvascular spasm. CMD is typically the mechanism underlying myocardial ischemia in individuals with angina despite completely normal coronary arteriograms, also known as primary MVA, 9 but it can also trigger myocardial ischemia in several other clinical conditions, including systemic hypertension, cardiomyopathies, and obstructive CAD (Figure 1 ). 22 Indeed, CMD can coexist with epicardial CAD, causing or contributing to myocardial ischemia and providing additional prognostic value over and above the presence of CAD.
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Structural and Functional Abnormalities CMD can result from structural or functional alterations of the coronary microvasculature. The relative importance of these mechanisms may vary in different clinical conditions and patient subsets. CMD because of structural changes of the microvasculature has been documented in patients with risk factors for CAD and different cardiomyopathies and is due to capillary rarefaction and adverse remodeling of intramural coronary arterioles. The latter results from medial wall thickening mainly because of smooth muscle hypertrophy and increased collagen deposition, with variable degrees of intimal thickening and a reduced wall/lumen ratio. An important feature here is the diffuse nature of this remodeling, which generally affects the coronary microvessels in the whole of the ventricle. 22 These structural changes can, even in the absence of epicardial CAD, induce progressive reductions in CFR mimicking the effects of flow limiting stenoses (Figures 1 and 2) . The difference, however, is that CFR reduction in patients with CMD rarely follows the regional (in the territory subtended by the stenotic artery) pattern seen in patients with obstructive CAD, rather appearing as patchy, 39 with small areas of ischemic tissue interspersed among otherwise normal myocardium, or diffuse, involving A, Coronary artery branching patterns: Type I pattern is characterized by multiple early intramural branches, type II distribution is directed to the subendocardial myocardium and papillary muscles with less initial branching, and type III consists of short branches that supply mainly the subepicardial myocardium. Transition to microcirculation corresponds to a diameter of <500 μm. Intramyocardial pressure progressively increases from the epicardium to the subendocardium. B, Small arteries are more responsive to flow-dependent dilatation, whereas large arterioles are more responsive to changes in intravascular pressure and are mainly responsible for autoregulation of coronary blood flow (CBF). Arterioles are more responsive to changes in the intramyocardial concentration of metabolites and are mainly responsible for the metabolic regulation of CBF. The proportion of total resistance in epicardial arteries is negligible; small arteries account for 20% and arterioles are the largest accounting for 40%. Control mechanisms are listed by their importance in the global control of the segment of microcirculation. P indicates coronary pressure; LV, left ventricle; and Q, coronary blood flow. Reprinted from Camici et al 28 with permission from the publisher. Copyright © 2018 Elsevier Philadelphia. most of the left ventricle. Functional abnormalities leading to CMD include impaired dilatation or excessive coronary microvascular constriction. Impaired vasodilatation may be because of abnormalities in endothelium-dependent mechanisms (frequently associated with diabetes mellitus, obesity, smoking, and other cardiovascular risk factors), endothelialindependent mechanisms, or both. 12, 40 Inflammation is another potentially important cause of CMD, as recently reviewed by Faccini et al. 41 Coronary microvascular spasm, originally described by Mohri et al, 13 can, similarly to epicardial coronary spasm, cause myocardial ischemia in the absence of increased myocardial demand and trigger rest angina. Structural and functional abnormalities can coexist in a given individual and may modulate the patient's ischemic threshold. 20 In patients with angina undergoing acetylcholine testing, Ong et al 38, 42 showed that ≈1 out of 4 patients had microvascular spasm, characterized by ischemic ECG changes without visible changes in the diameter of the epicardial coronary arteries (Figure 3 ). Arrebola-Moreno et al 43 reported that coronary microvascular spasm triggered by intracoronary ACh is associated with myocardial perfusion abnormalities, abnormal myocardial contractility, and, in a proportion of patients, elevation of high-sensitivity cardiac troponin concentrations.
Coronary microvascular ischemia, cardiomyocyte injury, and stiffness are also likely to play a role in the pathophysiology of heart failure with preserved ejection fraction. 44, 45 In a recent study in >200 symptomatic patients without overt CAD, Taqueti et al 44 showed that impaired CFR was independently associated with diastolic dysfunction and adverse events, particularly hospitalization for heart failure with preserved ejection fraction ( Figure 4 ). 
Increased Intramyocardial Pressure
During the cardiac cycle, the pulsatile pattern of CBF follows typical physiological variations that are influenced by changes in intramyocardial and intracavitary pressures. 46 Because ≈90% of CBF occurs in diastole, CBF is vulnerable to the effect of increased extravascular pressure (eg, in left ventricular hypertrophy) 30 and left ventricular diastolic dysfunction, such as that caused by increased interstitial and perivascular fibrosis. 47 CBF is also impaired when arteriolar driving pressure in diastole is lower than intracavitary pressure, as seen in patients with severe aortic stenosis and in those with flow-limiting coronary stenoses. Furthermore, increased systolic intramyocardial and intracavitary pressures may negatively impact myocardial perfusion because the compression of intramural vessels during systole may hinder subendocardial vessels tone restoration in diastole, thus impairing diastolic perfusion, particularly in the subendocardial layers. 48 
Reduced Diastolic Filling Time
Because CBF occurs predominantly during diastole, diastolic time plays a central role in preserving myocardial perfusion. In the normal heart, both subendocardial and subepicardial perfusion are maintained even with short diastolic times, such as during intense physical exercise. In contrast, when coronary driving pressure is significantly lower than intracavitary pressure, as in patients with aortic stenosis, a reduction of diastolic time can contribute to a critical impairment of myocardial perfusion. 49 
Myocardial Ischemia in ACS
Atheromatous Plaque-Related Mechanisms For decades, atheromatous plaque rupture with thrombus formation has been considered the main pathogenic mechanism underlying acute myocardial ischemia and myocardial infarction. Yet current evidence suggests that a sole focus on plaque rupture oversimplifies what is actually a complex clinical syndrome. Coronary artery thrombosis because of plaque erosion and leading to ACS/non-ST-elevation myocardial infarction (non-STEMI) is on the rise in the current era of intense lipid-lowering treatment. Moreover, in about one third of patients, ACS can occur in the absence of epicardial coronary artery thrombosis or stenosis. In a recent review article, Crea and Libby 50 recommended a mechanistic approach to the categorization of ACS highlighting the role of plaque erosion, inflammation, epicardial spasm, and microvascular disease. This approach provides a useful clinical framework for triaging patients at risk and tailoring therapy in a more personalized and precise manner. 50 
Coronary Microvascular Obstruction
Myocardial reperfusion in STEMI may be associated with a secondary impairment of the coronary microcirculation because of endothelial swelling, microvascular spasm, external compression, and distal embolization by plaque debris and platelet-leukocyte aggregates resulting in coronary microvascular obstruction (CMVO). 39, 40, 51 The latter prevents effective reperfusion of the ischemic region despite successful recanalization of the culprit vessel (no reflow). 52 No reflow can be diagnosed during coronary angiography using the TIMI trial (Thrombolysis In Myocardial Infarction) flow grade, TIMI myocardial blush grade, and TIMI frame count.
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Figure 4. Coronary microvascular dysfunction leading to reduced coronary flow reserve is associated with heart failure with preserved ejection fraction (HFpEF) and impaired clinical outcomes. This figure shows adjusted freedom from major adverse cardiovascular events and hospitalization for HFpEF by coronary flow reserve. Reprinted from et al 44 with permission. Copyright ©2018, Oxford University Press. *Cardiovascular death or hospitalization for myocardial infarction or heart failure. **Adjusted for pretest clinical score, history of atrial fibrillation, estimated glomerular filtration rate <60 ml/min
, detectable cardiac troponin, left ventricular ejection fraction, and E/e' septal >15.
Tissue Edema
Changes in capillary permeability, favoring migration of intravascular fluid into the interstitium, can cause myocardial edema and contribute to CMD through extravascular compression. Edema results from a combination of mechanisms, including increased interstitial osmolality and vascular permeability, abnormal ionic transport, and inflammation. 54 Coronary microvascular compression favors both intravascular plugging by neutrophil-platelet aggregates and CMVO. Edema can further impair CBF in the STEMI setting. 47, 48 Noninvasive assessment of intramyocardial hemorrhage, 55 myocardial edema, and CMVO can be carried out using T2-based and inversion recovery cardiac magnetic resonance imaging. 28 CMD of different types, as described in previous sections of this article, can trigger unstable angina, non-STEMI, or STEMI (acute MVA). In this context, 2 conditions have captured the attention of physicians worldwide (ie, MINOCA and Takotsubo syndrome). Both have been reviewed extensively elsewhere 23, 25, 56 and will not be discussed in detail here. A recent large study showed that ≈8% of all patients with AMI are MINOCA cases. 6 Other studies report a prevalence ranging from 1% to 14%. 9, 57 It is not known, however, what proportion of MINOCA cases are because of CMD as opposed to other mechanisms. Regarding Takotsubo syndrome, several authors have suggested that CMD and, more specifically, coronary microvascular spasm are likely to be the underlying causes in a sizeable number of cases. 23, 24, 58 The diagnosis of acute MVA requires confirmation that no obstructive CAD is present and also documentation of CMD-in the absence of epicardial coronary spasm or acute coronary thrombosis-as the causal mechanism. The assessment of CMD, including microvascular spasm, requires the use of provocative tests with ACh or ergonovine during angiography. The high diagnostic yield of these tests, as discussed in previous sections of this article, indicates that they should be performed routinely as part of the diagnostic pathways for MINOCA and Takotsubo syndrome. Recent studies have shown that these tests are safe if and when carried out by experienced teams even during the acute phase of MINOCA. 59, 60 Clinical studies showed impaired outcomes in patients with NSTE-ACS and normal coronary arteries with rates of death or AMI of 1.2% and recurrence of unstable symptoms of 8.4% at 1-year follow-up. 61 In a more recent study in patients with MINOCA, the rate of death at 2.5-year follow-up was 11.8%. 57 The causal mechanism underlying the ACS in these patients was not specifically investigated. In relatively small prospective studies comparing clinical outcomes in acute versus stable MVA, no major cardiac events were observed in either group at a mean follow-up of 36 months. 62 Controversial results have been published regarding acute symptoms or rates of hospital readmission with ACS-MVA. 57, 62 In a recent study in patients with MINOCA and documented microvascular spasm, mortality at 3-year follow-up was 7.7%. 60 Large, prospective functional studies are needed to clarify the true role of CMD in Takotsubo syndrome and MINOCA.
MICROVASCULAR ANGINA
The term MVA typically describes myocardial ischemia triggered by CMD in the absence of CAD. Primary MVA is a term used to describe subjects with completely normal coronary arteriograms and no clinically identifiable causes for CMD and myocardial ischemia. 9 As discussed in previous sections of this review, MVA can occur in the presence of conditions such as diabetes mellitus, rheumatic diseases, and CAD and in subjects with cardiomyopathies and heart valve disease, such as aortic stenosis. 9 The following section deals with patients who, in the absence of obstructive CAD, have stable angina or angina equivalent symptoms and documented myocardial ischemia caused by a reduced CFR or microvascular spasm.
9,17,63
Prevalence
Larger numbers of patients than previously thought are now known to have angina in the absence of obstructive CAD, with NCDR (National Cardiovascular Data Registry) and WISE databases (Women's Ischemic Syndrome Evaluation) leading to estimations suggesting that in the United States, 3 to 4 million women and men with symptoms of angina may have no obstructive CAD. 18 Moreover, data from a large US registry 5 show that >60% of 398 978 patients undergoing diagnostic coronary arteriography for the assessment of stable angina had normal coronary arteries or nonobstructive CAD (stenoses <50%). This finding is particularly striking given that a large proportion of individuals in the study had ≥1 conventional risk factors for CAD, and 69% developed transient myocardial ischemia as assessed by noninvasive diagnostic tests. It needs to be mentioned, however, that the occurrence of chest pain in the absence of obstructive CAD is not necessarily synonymous with MVA. Hence, the prevalence of true MVA is likely to be lower than the prevalence of angina without obstructive CAD.
Clinical Presentation and Diagnosis
Stable MVA is characterized by effort-induced symptoms similar to those observed in patients with angina triggered by obstructive CAD. However, patients with MVA often also have angina at rest and a variable angina threshold, suggestive of dynamic coronary vasomotor changes. Other clinical differences that can help identify patients with MVA include, among others, prolonged episodes of chest pain and a relatively poor response to sublingual nitrates in many cases. 9, 17, 63, 64 Primary MVA is more common in peri-and postmenopausal women than in men, but the condition should not be considered to be 1 that affects women exclusively. It is important to note that both atypical chest pain and effort-induced dyspnea are common symptoms in MVA, particularly in women. In the latter, a history of oophorectomy and symptom exacerbation in specific phases of the menstrual cycle as seen in some patients should alert physicians as to the presence of MVA. Estrogen deficiency has been associated with the development of angina in patients with chest pain and angiographically normal coronary arteries. 65 In subjects with MVA secondary to cardiomyopathies, heart valve disease, and systemic diseases, symptoms and signs typical of these conditions are also present.
STATE OF THE ART
Diagnostic Criteria
Recently, the COVADIS study group (Coronary Vasomotor Disorders) 66 proposed the following diagnostic criteria for MVA: signs and symptoms of myocardial ischemia, reduced CFR (defined as the ratio of CBF during near maximal coronary vasodilatation to baseline CBF) or microvascular spasm, and documented myocardial ischemia, which is not triggered by obstructive CAD but by functional or structural abnormalities at the site of the coronary microcirculation ( Table 2 ). The following clues are useful clues for the diagnosis of MVA:
1. Symptoms suggestive of myocardial ischemia. Typical chest pain will alert as to the possible ischemic nature of the symptoms, but chest pain can have atypical features in patients with MVA. The presence of both effort and rest angina suggests a possible coexistence of reduced coronary microvascular dilatory function and microvascular (or epicardial) spasm. 64 Angina occurring exclusively at rest will point toward epicardial or microvascular spasm as the prevailing mechanism. 2. Absence of obstructive CAD or objective demonstration that CAD is not responsible for myocardial ischemia. Excluding angiographic atheroma or establishing that a stenosis has no effect on coronary physiology (ie, normal fractional flow reserve) strongly suggests a microvascular origin of symptoms. 67 3. Objective documentation of myocardial ischemia. Documentation includes typical ST segment changes during chest pain as assessed by 12-lead ECG exercise stress testing or 12-lead Holter monitoring or ischemic findings on stress echocardiography, single photon emission tomography, or cardiac magnetic resonance perfusion scanning. In a sizeable proportion of patients with MVA, these imaging modalities will give negative results-despite the occurrence of ischemiabecause, contrary to what is seen in obstructive CAD, myocardial ischemia does not follow a regional pattern in MVA and ischemia may be in many cases limited to the subendocardium. 17, 39 4. Demonstration of coronary microvascular dysfunction. Functional CMD (ie, reduced CFR or microvascular spasm) can be investigated during angiography using intracoronary adenosine and ACh. The latter is considered to be the gold standard for the assessment of endothelial-dependent coronary vasodilatation. Adenosine, a powerful endothelial independent dilator of the coronary microcirculation, is used to assess fractional flow reserve, CFR, and the index of microcirculatory resistance (IMR) in the catheterization laboratory. CFR measurements reflect CBF changes influenced by both the epicardial and microvascular compartments, and, in the absence of obstructive CAD, CFR is a good marker of CMD. IMR has been suggested to provide good reproducible assessment of CMD independently from hemodynamic changes. 68 An exhaustive description of techniques used to assess CMD is beyond the scope of this article. However, recent publications highlight the ability of fractional flow reserve and IMR to more specifically assess epicardial vessel and Reprinted from Ong et al 66 with permission from the publisher. Copyright ©2018 Elsevier. 70 Noninvasive assessment of CMD can be carried out using positron emission tomography (PET), cardiac magnetic resonance, 69, 71 and pulsed-wave Doppler assessment of CBF on the left anterior descending coronary artery. [72] [73] [74] [75] [76] In 2012, Ong et al 38 reported that in patients with effort-induced stable angina and nonobstructive CAD (≈50% of the total study population), intracoronary Ach, at the time of diagnostic angiography, triggered distal epicardial spasm or microvascular spasm in >60% of patients. Coronary microvascular spasm, however, is a challenging diagnosis because intracoronary ACh may affect both the epicardial vessels and the microvasculature when endothelial dysfunction is present, thus making it difficult to diagnose microvascular spasm in isolation. Ergonovine, an ergot alkaloid acting on serotonin receptors in the coronary artery, has also been used extensively for the diagnosis of coronary artery spasm 77 with results that are similar to those of ACh. 36, 37 Both tests have been shown to be safe when performed by experienced operators and following suitable drug administration protocols.
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Clinical Outcomes and Economic Impact
Contrary to prior opinion, 17, 79 more recent studies have shown that prognosis in patients with angina despite the absence of obstructive CAD is not necessarily benign. 21, [80] [81] [82] Both men and women with angina who had impaired CFR despite nonobstructive CAD appear, in different series, to have worse clinical outcom es. 11, 19, 44, [83] [84] [85] [86] [87] As recently reviewed by Bairey-Merz et al, 10 almost two thirds of women undergoing clinically indicated coronary angiography for suspected CAD in the original WISE cohort had ischemia with no obstructive CAD. 11, 18 During follow-up, they had a risk rate for major adverse cardiac event (death, nonfatal MI, nonfatal stroke, and hospitalization for heart failure) of >2.5% yearly by 5 years, as well as elevated rates of hospital readmission and repeat angiography. At 10 years, cardiovascular death or myocardial infarction occurred in 6.7% of those with no evident angiographic CAD and in 12.8% of those with nonobstructive CAD. 88 In the WISE database, invasively assessed CFR <2.32 was the best predictor of adverse outcomes, with a 5-year major adverse cardiac events rate of 27% versus 9.3% for women with a CFR ≥2.32 (P=0.01) Similar outcome findings have been reported using noninvasive assessment of CFR with transthoracic echo Doppler or PET. 19, 86, 89 One of the problems that hampers the assessment of clinical outcomes in patients with angina without obstructive CAD is that studies have used broad and different inclusion criteria, resulting in heterogeneous groups being assessed. Large, prospective studies in well-characterized patients are required to clarify the natural history of angina without obstructive CAD.
In addition to increased rates of adverse cardiovascular events, these patients have an impaired quality of life. 63, 90 Moreover, they undergo multiple diagnostic investigations, a strategy that imposes a substantial financial burden on health services. In the United States and Europe, healthcare costs related to angiography and hospital admission in these individuals are similar to those in patients with obstructive CAD. 91 Taking all of this together, it is apparent that diagnostic strategies leading to a firm diagnosis of MVA are desirable. Albeit not as yet tested in a clinical trial, we propose a diagnostic algorithm based on our own clinical practice and suggestions by other authors aimed at identifying MVA and characterizing its pathogenic mechanisms ( Figure 5 ).
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Management
The management of MVA represents a major unmet need because the lack of large, randomized studies involving homogenous patient groups makes it difficult to generate evidence-based recommendations. Recent papers have discussed the management of patients with ischemia and nonobstructive CAD 10, 92 and suggested potential therapies for CMD. 10 These recommended therapies, however, are not always based on the pathogenesis of MVA, which would be desirable. 93 This section briefly discusses treatment options, taking into consideration currently accepted pathogenic mechanisms of CMD and MVA. Key objectives of the proposed management strategy areto (1) improve or abolish myocardial ischemia addressing its mechanisms/ causes; (2) improve quality of life; and (3) improve prognosis, identifying, and tackling mechanisms associated with impaired clinical outcomes. Targets to be addressed include endothelial dysfunction and risk factors, myocardial ischemia caused by impaired dilatory ability of the coronary microvessels or microvascular spasm, and chest pain-increased nociception.
Manage Endothelial Dysfunction, Modifiable Cardiovascular Risk Factors, and Lifestyle
A majority of patients with primary MVA and CMD have endothelial dysfunction, and studies using intravascular ultrasound have shown nonobstructive CAD to be present in a large proportion of patients. 94 Aggressive management of all modifiable conventional risk factors (eg, hypertension, diabetes mellitus, smoking, obesity, sedentary lifestyle, hyperlipidemia, etc) is of paramount importance in most subgroups of patients with MVA. 95 fects in individuals with coronary endothelial or vascular smooth muscle dysfunction despite nonobstructive CAD. [97] [98] [99] [100] [101] Angiotensin-converting enzyme inhibitors have also been shown to improve exercise tolerance and angina symptoms. 102, 103 Metformin improves endothelial function in patients with MVA without diabetes mellitus. 104 The American College of Cardiology/American Heart Association chronic stable angina guidelines 2 recommend the use of aspirin in patients with myocardial ischemia and no obstructive CAD, but this is not a strong recommendation.
Prevent and Treat Myocardial Ischemia Acting on Pathogenic Mechanisms
Robust evidence for the efficacy of antianginal agents in the treatment of MVA is lacking at present. Marinescu et al 105 carried out a systematic review of the efficacy of current treatment strategies in patients with CMD with CFR <2.5, as assessed by PET, cardiac magnetic resonance imaging, thermodilution methods, or intracoronary Doppler. Only 8 articles met the strict inclusion criteria established by the authors, and a major limitation was the small numbers of patients assessed in these studies.
Calcium channel blockers are likely to represent first-line agents for patients with documented microvascular spasm or abnormal CFR. Despite controversial data in small studies, 16, 106 expert consensus seems to highlight the use of calcium channel blockers as the preferred initial option when vasomotor abnormalities, particularly microvascular spasm, are suspected or documented. Nitrates do not appear to have major beneficial effects in MVA. In fact, <50% of patients report improved symptoms with the use of sublingual nitroglycerin, and a sizeable number have no benefit from oral nitrates. Similarly, little if any evidence exists at present for the use of L-arginine, the precursor of nitric oxide, to improve CMD. 107 Conversely, nicorandil, a potassium ATP channel opener with nitrate-like actions, has been reported to have beneficial actions in patients with MVA. 108, 109 Fasudil, a rho-kinase inhibitor and a potent coronary dilator available in Japan for the management of epicardial coronary artery spasm, has also been shown to be effective in patients with CMD. 110 β-blockers, alone or in combination with vasodilators, are (1) Some patients come to the specialist's attention after having had a coronary angiogram that shows no obstructive coronary artery disease. The challenge then is to document (usually by noninvasive means) whether these individuals have a reduced coronary flow reserve and also to identify functional and structural mechanisms that can be responsible for coronary microvascular dysfunction and myocardial ischemia. (2) The second scenario is that of patients presenting with signs of myocardial ischemia who had not up to that point been investigated invasively to determine the cause of their angina. CFR indicates coronary flow reserve; CMRI, cardiac magnetic resonance; ECHO, echocardiogram; FFR, fractional flow reserve; IMR, index of microvascular reserve; PET, positron emission tomography; and SPECT, single photon emission computed tomography.
useful in patients with MVA with predominantly effortinduced myocardial ischemia in whom a reduction in myocardial oxygen demand may increase exercise capacity. 9, 111, 112 However, caution is required regarding the use of β-blockers (particularly those lacking vasodilating properties) in patients with microvascular or epicardial spasm because these agents may increase coronary vasoconstriction by unmasking α-adrenoceptors in the coronary circulation. Another agent that reduces myocardial oxygen demand through its bradycardic effects is ivabradine, but little information exists at present regarding the efficacy of this agent in people with MVA. In small pilot studies of MVA trimetazidine, a metabolic modulator that shifts cardiac metabolism away from fatty acid oxidation to improve myocardial metabolism during ischemia, effectively improved symptoms and exercise capacity. 113 Ranolazine, an inhibitor of the late sodium current, 114 improved symptoms and CFR in women with no obstructive CAD and myocardial ischemia associated with CMD. In other studies, however, [115] [116] [117] including a randomized trial, 117 ranolazine had no beneficial effects on CMD, 116 symptoms, or myocardial perfusion reserve when all patients were considered, although the subgroup of patients with MVA with a markedly reduced CFR showed an improved response.
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Addressing the Problem of Abnormal Nociception
Because abnormal cardiac nociception may be the main cause for chest pain in some patients with MVA, 118 tricyclic antidepressants (ie, imipramine) have been proposed for treatment. Acting centrally, these agents have modulatory effects on norepinephrine uptake and anticholinergic actions that may result in analgesia. Imipramine has been shown to improve chest pain in subjects without obstructive CAD, 119 but side effects requiring discontinuation of the drug are common. 120 In patients with cardiac syndrome X, xanthine derivatives such as aminophylline were suggested to have analgesic effects resulting from adenosine receptor blockade. They may also have antiischemic actions through attenuation of the coronary microvascular steal phenomenon reported in patients with MVA. Aminophylline improves exercise tolerance and exercise-induced myocardial ischemia in patients with chest pain despite angiographically normal coronaries. [121] [122] [123] Nonpharmacological treatments such as spinal cord stimulation, transcutaneous nerve stimulation, enhanced external counter pulsation, cognitive behavioral therapy, and other psychological treatments, programmed exercise and cardiac rehabilitation have been proposed to be effective in managing chest pain. However, these have been generally assessed in small studies often involving heterogeneous groups of patients, making it difficult to issue strong evidencebased recommendations at this point in time.
CORONARY MICROVASCULAR DYSFUNCTION IN PATIENTS WITH OBSTRUCTIVE CAD
Three clinical scenarios have been described where CMD is the underlying mechanism of myocardial ischemia, or a major contributor, in patients with obstructive CAD. The first is represented by the fact that CFR may be abnormal in territories subtended by flow limiting stenoses as well as in regions supplied by arteries without stenosis, 124 suggesting that CMD and CAD can coexist and contribute, perhaps synergistically, to the development of myocardial ischemia in some individuals. The second relates to persistent or recurrent angina after successful percutaneous coronary intervention (PCI) and coronary stenting. The third relates to CMVO after primary PCI.
Evidence of the importance of CMD in patients with CAD has been provided by PET studies showing that the inclusion of CFR in risk prediction models resulted in more precise reclassification of risk of events at followup. 19 Furthermore, van de Hoef et al 125 assessed CFR invasively in nonobstructed coronary artery branches in 178 patients with obstructive CAD on diagnostic coronary angiography. After multivariable adjustment, CFR ≤2.7 was associated with a 2.24-fold increase in allcause mortality hazard. Similar findings were reported by Gupta et al 126 in 4029 consecutive patients (median age 66 years, 50.5% women) with known or suspected CAD who had been referred for rest or stress myocardial perfusion positron emission tomography scans (Figure 6) . Moreover, in a prospective, multicenter, observational study in 4313 patients with known or suspected CAD, Cortigiani et al 87 showed that CFR ≤2 as assessed by transthoracic Doppler echocardiography and inducible wall motion abnormalities on stress echocardiography were independent predictors of mortality. Conversely, normal stress echocardiographic results and CFR conferred an annual risk of death <1%. Also, in a study involving 329 consecutive patients undergoing stress testing with myocardial perfusion PET and invasive coronary angiography, Taqueti et al 127 showed that while global CFR was only modestly associated with the overall extent and severity of angiographic disease, a low CFR was strongly and independently associated with adverse clinical events. Also of interest in this study, only patients with a low CFR appeared to benefit from myocardial revascularization using coronary artery bypass surgery. Taken together, these data highlight the importance of CMD as a contributor to ischemia, a marker for risk stratification, and guidance to devise successful treatment strategies in patients with obstructive CAD. Although challenged by a recent study comparing PCI with a sham procedure, 128 there is general agreement that PCI has some advantages over optimal medical treatment regarding symptom control.
STATE OF THE ART
2,4 Yet a sizeable proportion of patients continue to experience angina after successful myocardial revascularization with PCI. [129] [130] [131] [132] [133] In the COUR-AGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation), 47% of patients randomized to PCI had persistent angina at 3-month followup, and the differences in angina prevalence favoring patients randomized to PCI and optimal medical treatment versus those randomized to optimal medical treatment only decreased over time and became nonsignificant at 3-year follow-up. 134 Similar findings were observed in other prospective trials and meta-analyses. [130] [131] [132] [133] Thus, angina after PCI represents an important clinical problem, affecting ≈20% to 50% of patients at 1-year follow-up. Data from the FAME 2 trial (Fractional Flow Reserve versus Angiography for Multivessel Evaluation), however, indicate that when fractional flow reserve guidance is used to identify flow-limiting stenoses, the rate of residual chest pain after PCI is significantly lower. 135 The pathophysiology of angina persisting or recurring after successful PCI is complex and involves both structural and functional mechanisms. Structural causes of angina after PCI include in-stent restenosis, stent thrombosis, progression of atherosclerotic disease in other coronary segments, incomplete revascularization, and diffuse atherosclerosis without focal stenosis. Functional causes include vasomotor abnormalities of epicardial coronary arteries or CMD. Regarding the latter, Ong et al 42 showed that in 51 of 104 patients (49%) undergoing coronary angiography for recurrent angina after PCI despite patent stents, epicardial or microvascular coronary spasm, as assessed with ACh provocation, was responsible for the patients' symptoms.
Highlighting the role of CMD in angina after PCI, Li et al 136 found a greater reduction of CBF and a larger (intracoronary thermodilution method increase in patients with recurrent angina after PCI compared with patients without recurrent angina. Similar findings were reported by Milo et al 137 using transthoracic Doppler echocardiography of the left anterior descending coronary artery. CFR was reduced at 3-and 6-month follow-up in patients with myocardial ischemia on stress testing after successful PCI but not in those with normal stress test responses. It has been suggested that drug-eluting stent implantation might amplify preexisting functional abnormalities of the coronary circulation. 138, 139 In the primary PCI setting, CMVO has been shown to be associated with adverse left ventricular remodeling, a higher risk of cardiac death, recurrent myocardial infarction, and heart failure-related rehospitalization. 140, 141 Experimental and clinical studies have shown that CMVO is caused by a combination of 4 pathogenic components: ischemic injury, reperfusion injury, distal embolization, and individual susceptibility to reperfusion injury. 40 An individual susceptibility to microvascular dysfunction (ie, genetic factors) may modulate adenosine-induced vasodilation in this setting. In particular, the 1976T.C polymorphism of the adenosine 2A receptor gene was found to be associated with a higher prevalence of CMVO. 51 Further research is needed to gain insight into the molecular mechanisms, pathophysiology, prevention, and treatment of CMVO.
CONCLUSIONS
The information reviewed in this article suggests that CMD plays a substantial pathogenic role across the spectrum of ischemic heart disease and indicates that MVA caused by CMD can affect large numbers of patients, In a large cohort of 4029 patients with known or suspected CAD and a median follow-up of 5.6 years, Gupta et al 126 found that CFR was a stronger independent predictor of cardiovascular mortality than maximal myocardial blood flow. The figure shows event curves for probability of cardiovascular mortality over time for the 4 groups based on concordant or discordant impairment of CFR and maximal myocardial blood flow. A, Unadjusted event curves. B, Event curves after adjustment for age, sex, baseline cardiovascular risk factors, left ventricular ejection fraction, amount of myocardial scar and ischemia, revascularization after positron emission tomography scan, rate-pressure product, and type of radiotracer or stress agent. CFR indicates coronary flow reserve; CV, cardiovascular; and MBF, myocardial blood flow. Reprinted from Gupta et al 126 with permission from the publisher. Copyright © 2017 Wolters Kluwer.
including subjects with no obstructive CAD and individuals with obstructive CAD, as well as those with persisting angina after anatomically successful coronary recanalization. Structural and functional mechanisms affecting the coronary microcirculation can lead to myocardial ischemia. Progress in the diagnosis of myocardial ischemia and the availability of tests to investigate CFR and coronary vasomotion in recent years has allowed for better identification and characterization of patients with MVA in everyday clinical practice. Clinical outcome is not necessarily benign in MVA, and efforts should be made to identify these individuals at an early stage of their disease. Treatment of the different forms of MVA discussed in this article remains a major unmet need, but strategies exist that can help improve patients' quality of life. Hopefully, future international guidelines on the management of angina will highlight the growing importance of CMD and MVA in the field of ischemic heart disease. 
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